The Stock Exchange of Hong Kong has notified China Tian Yuan Healthcare Group Limited that it failed to maintain sufficient operations and assets under Rule 13.24. Consequently, the company faces a trading suspension effective 2 December 2026 unless it requests a review by 1 December 2026.
On 20 November 2026 the Stock Exchange decided the Company failed to maintain sufficient operations and assets under Rule 13.24, and trading in its shares (Stock Code 557) will be suspended under Rule 6.01(3). A suspension plus delisting risk is a direct, severe negative for the stock, compounded by revenue collapsing from HK$94.6 million in 2021 to HK$19.8 million in 2025 with net losses every year. Nothing in the letter mitigates the decision.
- ▼ Exchange letter dated 20 November 2026 ordering trading suspension under Rule 6.01(3)
- ▼ Revenue decline from HK$94.6 million (2021) to HK$19.8 million (2025) with net losses in all five years
- ▲ Trading suspension blocks existing holders from selling shares
- ▲ Remaining businesses judged small, not viable or sustainable